The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • The variant label for this record ("m.15197T>C") does not appear to be in HGVS format
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: MT-CYB CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: m.15197T>C

CA120620

9682 (ClinVar)

Gene: MT-CYB
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 00f4f82b-2842-4b1a-8802-aef2dd49ac1e
Approved on: 2024-01-08
Published on: 2024-07-24

HGVS expressions

NC_012920.1:m.15197T>C
J01415.2:m.15197T>C
ENST00000361789.2:c.451T>C

Uncertain Significance

Met criteria codes 2
PM2_Supporting PP3
Not Met criteria codes 5
PM6 PS3 PS2 PS4 PP1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.15197T>C (p.S151P) variant in MT-CYTB has been reported in one individual with primary mitochondrial disease to date. This individual had exercise intolerance in early childhood and had the variant present at 80% heteroplasmy in muscle. The variant was undetectable in blood and skin fibroblasts. Complex III activity was reduced at 17% of controls in muscle, 28% in blood, and 50% in skin fibroblasts (PMID: 11454242). There are no reports of large families with this variant segregating with disease. There are no reported de novo occurrences of this variant to our knowledge. This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.72 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). There are no cybrids, single fiber studies, or other functional assays reported on this variant. In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on January 8, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PM2_supporting, PP3.
Met criteria codes
PM2_Supporting
This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting).
PP3
The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.72 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3).
Not Met criteria codes
PM6
There are no reported de novo occurrences of this variant to our knowledge.
PS3
There are no cybrids, single fiber studies, or other functional assays reported on this variant.
PS2
There are no reported de novo occurrences of this variant to our knowledge.
PS4
The m.15197T>C (p.S151P) variant in MT-CYTB has been reported in one individual with primary mitochondrial disease to date. This individual had exercise intolerance in early childhood and had the variant present at 80% heteroplasmy in muscle. The variant was undetectable in blood and skin fibroblasts. Complex III activity was reduced at 17% of controls in muscle, 28% in blood, and 50% in skin fibroblasts (PMID: 11454242).
PP1
There are no reports of large families with this variant segregating with disease.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.